Background Many potential environmental risk factors, environmental protective factors, and
peripheral biomarkers for ADHD have been investigated, but the consistency and magnitude …

In recent years, the published literature has suggested the key involvement of the cytokine
interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have …

Background Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13,
prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor …

The design and interpretation of clinical studies requires consideration of variables beyond
the exposure or treatment of interest and patient outcomes, including decisions about which …

Background Nemolizumab is a subcutaneously administered humanized monoclonal
antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in …

Summary Background Interleukin (IL)‐31 affects the inflammatory response, is involved in
epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus …

Background Molecular studies in atopic dermatitis (AD) are largely restricted to patients with
moderate-to-severe disease. Objective Our aim was to evaluate skin and blood …

Sleep quality is one of the domains of sleep. Having adequate quality sleep is defined as
one's “feeling fresh” after waking-up. Inadequate sleep quality results in sleep insufficiency …

Background Dupilumab has demonstrated efficacy and acceptable safety in adults and
children (aged 6–17 years) with moderate‐to‐severe atopic dermatitis (AD), but effective …

Objective To evaluate the impact of atopic dermatitis on families of pediatric patients. Study
design This cross-sectional, web-based survey of children/adolescents (6 months to< 18 …